Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- M4M-FIP label "M4M FIP workshop" assertion.
- workshop label "short ID of workshop" assertion.
- name label "the name of the workshop" assertion.
- workshoptype label "choose the type of the workshop" assertion.
- date label "date of the workshop (e.g. 2020-12-01)" assertion.
- assertion label "Defining an M4M workshop" assertion.
- workshoptype label "choose the type of the workshop" assertion.
- name label "the name of the workshop" assertion.
- workshop label "short ID of workshop" assertion.
- date label "date of the workshop (e.g. 2020-12-01)" assertion.
- assertion label "Defining an M4M workshop" assertion.
- somebodyElse label "ORCID identifier of the person to be attributed" assertion.
- assertion label "Attributed to somebody else" assertion.
- cohort label "Adults" assertion.
- association label "Recently, off label use of modafinil (MOD), an approved medication for treatment of sleep disturbances, has been tested as a therapeutic for cocaine and methamphetamine use disorder. Positive results have been found in subjects dependent on psychostimulants without concurrent abuse of other substances." assertion.
- cohort label "Adults" assertion.
- association label "Recently, off label use of modafinil (MOD), an approved medication for treatment of sleep disturbances, has been tested as a therapeutic for cocaine and methamphetamine use disorder. Positive results have been found in subjects dependent on psychostimulants without concurrent abuse of other substances." assertion.
- cohort label "Adults" assertion.
- association label "Recently, off label use of modafinil (MOD), an approved medication for treatment of sleep disturbances, has been tested as a therapeutic for cocaine and methamphetamine use disorder. Positive results have been found in subjects dependent on psychostimulants without concurrent abuse of other substances." assertion.
- association label "Tazodone, a serotonin modulator, is used off-label for insomnia." assertion.
- cohort label "Adults" assertion.
- association label "Trazodone is also used off-label for anxiety, Alzheimer disease, substance abuse, bulimia, and fibromyalgia due to its serotonergic receptor antagonism and serotonin reuptake inhibiting effects." assertion.
- cohort label "Adults" assertion.
- association label "Trazodone is also used off-label for anxiety, Alzheimer disease, substance abuse, bulimia, and fibromyalgia due to its serotonergic receptor antagonism and serotonin reuptake inhibiting effects." assertion.
- cohort label "Adults" assertion.
- cohort label "Adults" assertion.
- association label "Trazodone is also used off-label for anxiety, Alzheimer disease, substance abuse, bulimia, and fibromyalgia due to its serotonergic receptor antagonism and serotonin reuptake inhibiting effects." assertion.
- cohort label "Adults" assertion.
- association label "In this activity, augmentation and adjunctive strategies involving atypical antipsychotics, as well as off-label options including buspirone, stimulants, thyroid hormone, and lithium, are reviewed. ." assertion.
- cohort label "Adults" assertion.
- association label "It also has off label use as monotherapy or adjunctive therapy for the treatment of mania, restless leg syndrome, insomnia, tardive dyskinesia, and REM sleep behavior disorder." assertion.
- cohort label "Adults" assertion.
- association label "It also has off label use as monotherapy or adjunctive therapy for the treatment of mania, restless leg syndrome, insomnia, tardive dyskinesia, and REM sleep behavior disorder." assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- cohort label "Adults" assertion.
- cohort label "Adults" assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- cohort label "Adults" assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- cohort label "Adults" assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- association label "Off-label use includes treatment of cholestatic pruritus in adults." assertion.
- cohort label "Adults" assertion.
- association label "Sedating antidepressants (e.g., amitriptyline, trazodone, mirtazapine) are often prescribed off-label as sleeping aids" assertion.
- cohort label "Adults" assertion.
- cohort label "Children and adolescents" assertion.
- association label "Melatonin (97%), trazodone (81%), and quetiapine (73%) were rated by a majority of respondents as effective. Doxepin, zaleplon, tricyclic antidepressants, zolpidem, or lorazepam were rarely prescribed due to lack of evidence and/or concerns about adverse effects, long-term safety, suitability for youth, suicidality, and dependence/tolerance." assertion.
- association label "Melatonin (97%), trazodone (81%), and quetiapine (73%) were rated by a majority of respondents as effective. Doxepin, zaleplon, tricyclic antidepressants, zolpidem, or lorazepam were rarely prescribed due to lack of evidence and/or concerns about adverse effects, long-term safety, suitability for youth, suicidality, and dependence/tolerance." assertion.
- cohort label "Children and adolescents" assertion.
- cohort label "Children and adolescents" assertion.
- association label "Melatonin (97%), trazodone (81%), and quetiapine (73%) were rated by a majority of respondents as effective. Doxepin, zaleplon, tricyclic antidepressants, zolpidem, or lorazepam were rarely prescribed due to lack of evidence and/or concerns about adverse effects, long-term safety, suitability for youth, suicidality, and dependence/tolerance." assertion.
- cohort label "Children and adolescents" assertion.
- association label "Melatonin (97%), trazodone (81%), and quetiapine (73%) were rated by a majority of respondents as effective. Doxepin, zaleplon, tricyclic antidepressants, zolpidem, or lorazepam were rarely prescribed due to lack of evidence and/or concerns about adverse effects, long-term safety, suitability for youth, suicidality, and dependence/tolerance." assertion.
- association label "Prescriptions for antipsychotic medications continue to increase across many brain disorders, including off-label use in children and elderly individuals." assertion.
- cohort label "Elderly; adults" assertion.
- spi label "the protein TDP-43 represses cryptic exon inclusion in the gene UNC13A" assertion.
- creator label "ORCID identifier of the person who performed the formalization" assertion.
- activity label "Formalization-Activity" assertion.
- quote label "source quote" assertion.
- source label "URI of the source used by this formalization activity" assertion.
- assertion label "Generated by a formalization activity" assertion.
- M4M-workshop label "M4M workshop" assertion.
- M4M-vocabulary label "M4M vocabulary workshop" assertion.
- M4M-vocabulary label "M4M vocabulary workshop" assertion.
- M4M-vocabulary label "M4M vocabulary workshop" assertion.
- M4M-vocabulary label "M4M vocabulary workshop" assertion.
- M4M-vocabulary label "M4M vocabulary workshop" assertion.
- R4RM4M label "R4RM4M workshop" assertion.
- R4RM4M label "R4RM4M workshop" assertion.
- R4RM4M label "R4RM4M workshop" assertion.
- R4RM4M label "R4RM4M workshop" assertion.
- R4RM4M label "R4RM4M workshop" assertion.
- M4M-infrastructure label "M4M infrastructure workshop" assertion.
- M4M-infrastructure label "M4M infrastructure workshop" assertion.
- M4M-infrastructure label "M4M infrastructure workshop" assertion.
- M4M-infrastructure label "M4M infrastructure workshop" assertion.
- M4M-infrastructure label "M4M infrastructure workshop" assertion.
- FIP-workshop label "FIP workshop" assertion.
- FIP-workshop label "FIP workshop" assertion.
- FIP-workshop label "FIP workshop" assertion.
- FIP-workshop label "FIP workshop" assertion.
- FIP-workshop label "FIP workshop" assertion.
- association label "Single dispensings of haloperidol and amitriptyline may be related to off-label use for indications where evidence of risks and benefits is lacking, such as behavioural disturbances in dementia and insomnia." assertion.
- association label "However, studies have demonstrated that of all the antipsychotics, quetiapine is the most frequently used off-label to treat conditions such as insomnia and post-trau- matic stress disorder (McKean and Monasterio, 2012) and has been flagged as the most concerning in terms of lack of evidence to support these indications and potential to cause harm (Walton et al., 2008)." assertion.
- cohort label "Adults" assertion.
- association label "Of patients prescribed quetiapine for insomnia only, most common discharge diagnoses were anxiety disorder (35%), depressive disorder (27%), eating disorder (27%), and Cluster B/borderline personality traits/disorder (25%). Mean age was 15.4 years; mean maximum dose was 41.2 mg." assertion.
- cohort label "Children and adolescents" assertion.
- MONDO_0005618 label "Anxiety disorder" assertion.
- MONDO_0005618 label "Anxiety disorder" assertion.
- MONDO_0005618 label "Anxiety disorder" assertion.
- MONDO_0005618 label "Anxiety disorder" assertion.
- MONDO_0005618 label "Anxiety disorder" assertion.
- MONDO_0005618 label "Anxiety disorder" assertion.
- MONDO_0005618 label "Anxiety disorder" assertion.
- MONDO_0005618 label "Anxiety disorder" assertion.
- MONDO_0005618 label "anxiety disorder" assertion.
- cohort label "Children" assertion.
- association label "Off-label use of vilazodone in children under 6 years should be discouraged until further research is conducted regarding its safety in this population." assertion.
- MONDO_0002050 label "depressive disorder" assertion.
- MONDO_0002050 label "depression" assertion.